.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AA19_Eflapegrastim.Eflapegrastim .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AA19_Eflapegrastim.Eflapegrastim| name: | Eflapegrastim | |
| ATC code: | L03AA19 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 13.2 | mg |
| volume of distribution: | 0.11 | L |
| clearance: | 0.0272 | L/h/kg |
| other parameters in model implementation | ||
Eflapegrastim is a long-acting, recombinant human granulocyte colony-stimulating factor (G-CSF) analog, conjugated to a human IgG4 Fc fragment via a polyethylene glycol linker. It is used for the reduction in the duration of severe neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. It is approved for use in the United States.
Population pharmacokinetics in adult cancer patients; healthy volunteers and patients with breast cancer following subcutaneous administration.